🟢 Painreform is trading 5% up

Painreform is trading at $0.76, up 5.04%, with no verified company-specific catalyst identified for the October 27 move.

• The latest reported company update, on October 23, covered cash, OcuRing-K trial plans and GridFeed strategy.
• Biotech-sector strength may have provided a backdrop: XBI rose 2.18% amid positive trial and regulatory news, while the broader market was also higher. No verified link to Painreform’s gain was reported.